William Blair Weighs in on Avantor’s Q1 Earnings (NYSE:AVTR)

Avantor, Inc. (NYSE:AVTR) – Equities research analysts at William Blair lowered their Q1 2025 EPS estimates for shares of Avantor in a report released on Monday, October 28th. William Blair analyst M. Larew now expects that the company will post earnings per share of $0.25 for the quarter, down from their prior forecast of $0.29. The consensus estimate for Avantor’s current full-year earnings is $1.01 per share. William Blair also issued estimates for Avantor’s Q2 2025 earnings at $0.30 EPS and FY2025 earnings at $1.18 EPS.

AVTR has been the topic of several other research reports. UBS Group dropped their price objective on Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, October 8th. Stifel Nicolaus lifted their price objective on Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a report on Monday, July 29th. Barclays decreased their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Robert W. Baird dropped their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday. Finally, Wells Fargo & Company reduced their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $27.57.

Avantor Stock Down 0.3 %

Shares of NYSE:AVTR opened at $22.45 on Wednesday. The company has a 50 day moving average price of $25.32 and a two-hundred day moving average price of $24.21. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.05 and a current ratio of 1.59. The company has a market capitalization of $15.25 billion, a PE ratio of 57.56, a PEG ratio of 2.93 and a beta of 1.33. Avantor has a 52 week low of $17.06 and a 52 week high of $28.00.

Institutional Investors Weigh In On Avantor

A number of large investors have recently added to or reduced their stakes in AVTR. Jennison Associates LLC increased its stake in shares of Avantor by 113.0% during the first quarter. Jennison Associates LLC now owns 2,497,349 shares of the company’s stock worth $63,857,000 after purchasing an additional 1,325,026 shares during the period. Swedbank AB bought a new position in Avantor during the 1st quarter worth $2,707,000. Diversify Advisory Services LLC acquired a new stake in shares of Avantor during the first quarter worth $908,000. BNP Paribas Financial Markets boosted its position in shares of Avantor by 42.4% in the first quarter. BNP Paribas Financial Markets now owns 309,394 shares of the company’s stock valued at $7,911,000 after acquiring an additional 92,098 shares during the period. Finally, William Blair Investment Management LLC grew its stake in shares of Avantor by 44.6% in the first quarter. William Blair Investment Management LLC now owns 1,047,732 shares of the company’s stock valued at $26,791,000 after acquiring an additional 322,985 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Insider Activity

In other news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the transaction, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at $740,372.64. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.50% of the stock is currently owned by insiders.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.